An international surgical task force is designing a randomized controlled trial to evaluate a novel topical hemostatic agent for reducing intraoperative blood loss during major hepatic resections. The primary outcome is the total volume of blood lost (a continuous variable measured in milliliters). Initial power calculations dictate a required sample size of patients to detect a clinically significant difference of mL between the novel agent and standard care, assuming a significance level () of and statistical power (). However, due to the rarity of the specific surgical indications, the task force anticipates a maximum enrollment of only patients over the study period. Which of the following modifications to the study design is most appropriate to maximize the statistical power of the trial given the constrained sample size?
- Implementing a highly standardized, automated blood collection and weighing protocol to decrease measurement varianceAnswer
- BCategorizing the continuous blood loss data into binary outcomes (e.g., >500 mL vs. <500 mL) and analyzing it with a Chi-square test
- CStratifying the primary analysis into multiple small subgroups to evaluate for effect modification by patient age
- DChanging the primary analysis to evaluate the positive predictive value of the intervention based on regional disease prevalence
- EDecreasing the pre-specified significance level from 0.05 to 0.01 to prevent cognitive bias during data interpretation